Table 3.
Pharmacokinetic parameters derived from amulti-compartmental analysis of mean serum gliclazide profiles in the Caucasian and Aboriginal groups incorporating enterohepatic recirculation. Data are parameter estimates and (95% confidence intervals).
| Caucasian | Aboriginal | |
|---|---|---|
| Bioavailability (%) | 86 (83–90) | 89 (81–96) |
| Enterohepatic recycling (%) | 30 (8–53) | 20 (8–31) |
| Volume of distribution (l) | 9.8 (5.1–14.5) | 11.9 (9.6–14.1) |
| k(3,0) (h−1) | 0.08 (0.04–0.11) | 0.06 (0.01–0.11) |
| k(4,3) (h−1) | 0.30 (0.00–0.57) | 0.01 (0.00–0.02) |
| k(3,4) (h−1) | 0.07 (0.02–0.12) | 0.06 (0.02–0.10) |
| k(1,0) (h−1) | 1.5 (0.9–2.0) | 1.5 (0.5–2.4) |
| k(2,3) (h−1) | 7.7 (4.7–10.8) | 10.5 (8.8–12.3) |
| k(1,2) (h−1) | 9.6 (8.9–10.3) | 11.7 (10.2–13.1) |
| k(5,1) (h−1) | 25.4 (13.1–37.6) | 17.6 (10.9–24.2) |
| k(2,5) (h−1) | 3.4 (1.0–5.7) | 2.6 (1.1–4.1) |
| q2 delay (h) | 1.26 (1.14–1.38) | 1.07 (0.98–1.15) |
| q5 delay (h) | 1.10 (0.57–1.63) | 1.59 (0.99–2.19) |